Anixa Biosciences CEO purchased shares, company developing breast cancer vaccine targeting α-lactalbumin.

From Financial Modeling Prep: 2025-06-05 15:06:00

Kumar Amit, CEO of Anixa Biosciences, Inc. (NASDAQ:ANIX), recently purchased 10,000 shares, increasing his total ownership to 569,925 shares. The company’s breast cancer vaccine targets α-lactalbumin in malignant cells, aiming to revolutionize cancer prevention and treatment. Despite financial challenges, ANIX’s low debt-to-equity ratio and strong current ratio suggest a stable foundation for its projects.



Read more at Financial Modeling Prep:: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO’s Recent…